Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Tweet
Share
E-mailSAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.
Citi 2023 Virtual Oncology Leadership SummitFireside Chat: February 21st at 10:00 am ET
H.C. Wainwright Cell Therapy Virtual ConferenceFireside Chat: February 28th at 9:30 am ET One-on-one meetings: Tuesday, February 28th, 2023
A webcast of the presentations will be available on the News and Events section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.
About GracellGracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit http://www.gracellbio.com/. Follow @GracellBio on LinkedIn.
Media contact Marvin Tang [email protected] Investor contact Gracie Tong [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
- Blue Jay Gold Announces Nomination of Ashley Kates to the Board of Directors for Upcoming AGM
- ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
